Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
Pulling Back the Curtain: Vip Viprakasit, MD, DPhil
In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...
Let’s Get Cooking: Jonathan Hoggatt, PhD
In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.
Pulling Back the Curtain: Richard W. Childs, MD
Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...
Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia
Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
Pulling Back the Curtain: Richard W. Childs, MD
In this edition, Richard W. Childs, MD, talks about his accomplishments in immunotherapy, his role in the response to the 2014 West Africa Ebola...
Current Issue
October 2018, Volume 4, Issue 12
This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.
